Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
$4.62
-$0.11(-3.01%)
At close: 4:00 PM EST
$4.62
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.88 - $8.95
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$311.38M
Enterprise Value-$20.44M
Total Cash (Recent Filing)$74.65M
Total Debt (Recent Filing)$17.86M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 06, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding68,737,220
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.07
Enterprise Value/Revenue-13.70
Enterprise Value/Gross Profit57.57
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$9.60Price Target Upside107.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data PerformancePepGen's recent FREEDOM-DM1 data shows 53.7% mean splicing correction, the highest level reported in DM1 patients to date, with a favorable safety profile.
Market PositioningPepGen is viewed as a hidden gem in the field, undervalued yet strategically positioned for both a fundamental re-rating and potential M&A.
Price Target IncreaseAn increase in the probability of success to 35% and the target price to $12 reflects confidence in the positive data and financing updates.
Bears Say
Development ChallengesPEPG is behind competitors in development, and it remains unclear if an accelerated path will be open.
Safety ConcernsThe safety profile still needs de-risking due to potential readthrough from the discontinued DMD program, where asymptomatic cases of hypomagnesemia were observed.
Uncertain OutcomesClarity on the safety profile of PEPG’s proprietary EDO platform is still needed, given the readthrough risk from the discontinued DMD program.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $8.95 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $311.38M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Nov 06, 2025 which is 3 days ago.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Aug 07, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.146.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.57.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 68,737,220 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -7.269%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.60 (107.79% Upside)
$9.60 (107.79% Upside)
Hedge Fund Trend
Decreased
By 89.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-85.69%
Trailing 12-Months
Asset Growth
-47.16%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc. (PEPG) is a biotechnology company focused on developing transformative therapies for patients with neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to deliver innovative solutions that improve the delivery and efficacy of oligonucleotides. The company's core products are designed to address unmet medical needs through targeted treatments that can enhance the quality of life for patients suffering from debilitating conditions.
PEPG Stock 12 Month Forecast
Average Price Target
$9.60
▲(107.79% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
I-MAB
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
36.69% Insiders
1.90% Mutual Funds
23.98% Other Institutional Investors
34.71% Public Companies and
Individual Investors